Enhanced accumulation of curcumin and temozolomide loaded magnetic nanoparticles executes profound cytotoxic effect in glioblastoma spheroid model

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 85, Issue 3 PART A, 2013, Pages 452-462

  Dilnawaz, Fahima ^a   Sahoo, Sanjeeb Kumar ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

Cell death; Cytotoxicity; Glioblastoma; Magnetic nanoparticles; Synergistic; Tumour spheroids

Indexed keywords

ACRIDINE ORANGE; CURCUMIN; MAGNETIC NANOPARTICLE; PROPIDIUM IODIDE; TEMOZOLOMIDE;

ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL ASSAY; CELL DEATH; CELL PROLIFERATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG PENETRATION; DRUG POTENTIATION; DRUG UPTAKE; FLOW CYTOMETRY; GLIOBLASTOMA; IN VITRO STUDY; MONOLAYER CULTURE; OUTCOME ASSESSMENT; PHYSICAL CHEMISTRY; SPHEROID CELL; ZETA POTENTIAL;

CELL DEATH; CYTOTOXICITY; GLIOBLASTOMA; MAGNETIC NANOPARTICLES; SYNERGISTIC; TUMOUR SPHEROIDS;

ACRIDINE ORANGE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BRAIN NEOPLASMS; CELL CULTURE TECHNIQUES; CELL DEATH; CELL LINE, TUMOR; CURCUMIN; DACARBAZINE; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; GLIOBLASTOMA; HUMANS; MAGNETICS; NANOPARTICLES; PROPIDIUM; STAINING AND LABELING;

EID: 84888309273     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2013.07.013     Document Type: Article

References (51)

1. N. Avgeropoulos, and T. Batchelor New treatment strategies for malignant gliomas Oncologist 4 3 1999 209 224
2. E. Burton, and M. Prados Malignant gliomas Curr. Treat. Options Oncol. 1 2000 459 468
3. U. Fischer, and E. Meese Glioblastoma multiforme: the role of DSB repair between genotype and phenotype Oncogene 26 2007 7809 7815
4. S. Sathornsumetee, and J. Rich New approaches to primary brain tumor treatment Anticancer Drugs 17 2006 1003 1016
5. S. Grossman, and J. Batara Current management of glioblastoma multiforme Semin. Oncol. 31 2004 635 644
6. J. Kreuter Nanoparticulate systems for brain delivery of drugs Adv. Drug Deliv. Rev. 47 2001 65 81
7. W.M. Pardridge Transport of small molecules through the blood-brain barrier: biology and methodology Adv. Drug Deliv. Rev. 15 1-3 1995 5 36
8. L. Jabr-Milane, L. van Vlerken, S. Yadav, and M. Amiji Multi-functional nanocarriers to overcome tumor drug resistance Cancer Treat. Rev. 34 7 2008 592 602
9. J. Lehàr, A.S. Krueger, W. Avery, A.M. Heilbut, L.M. Johansen, E.R. Price, R.J. Rickles, G.F. Short III, J.E. Staunton, X. Jin, M.S. Lee, G.R. Zimmermann, and A.A. Borisy Synergistic drug combinations improve therapeutic selectivity Nat. Biotechnol. 27 7 2009 659 666
10. D.R. Budman, A. Calabro, L.G. Wang, X.M. Liu, L. Stiel, L.M. Adams, and W. Kreis Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro Cancer Invest. 18 8 2000 695 701
11. L. Mayer, T.O. Harasym, P.G. Tardi, N.L. Harasym, C.R. Shew, S.A. Johnstone, E. Ramsay, M.B. Bally, and A.S. Janof Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice Mol. Cancer Ther. 5 7 2007 1854 1863
12. L.A. Torres, M.A. Coca, J.F. Batista, A. Casaco, G. Lopez, I. GarcÍa, A. Perera, Y. Peña, A. Hernández, Y. Sanchez, S. Romero, R. Leyva, A. Prats, and R. Fernandez Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas Nucl. Med. Commun. 29 2008 66 75
13. S. Aryal, C. Hu, and L. Zhang Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy Mol. Pharm. 8 4 2011 1401 1407
14. K.M. Dhandapani, V.B. Mahesh, and D.W. Brann Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors J. Neurochem. 102 2007 522 538
15. H. Hatcher, R. Planalp, J. Cho, F.M. Torti, and S.V. Torti Curcumin: from ancient medicine to current clinical trials Cell. Mol. Life Sci. 65 2008 1631 1652
16. H. Aoki, Y. Takada, S. Kondo, R. Sawaya, B.B. Aggarwal, and Y. Kondo Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways Mol. Pharmacol. 72 2007 29 39
17. P. Luthra, R. Kumar, and A. Prakash Demethoxycurcumin induces Bcl-2 mediated G2/M arrest and apoptosis in human glioma U87 cells Biochem. Biophy. Res. Commun. 384 2009 420 425
18. S. Kim, S. Jung, and H. Kim Curcumin is a potent broad spectrum inhibitor of matrix metalloproteinase gene expression in human astroglioma cells Biochem. Biophys. Res. Commun. 337 2005 510 516
19. J. Weissenberger, M. Priester, C. Bernreuther, S. Rakel, M. Glatzel, V. Seifert, and D. Kögel Dietary curcumin attenuates glioma growth in a syngeneic pathway mouse model by inhibition of the JAK1,2/STAT3 signaling Clin. Cancer Res. 16 2010 5781 5795
20. H.S. Friedman, T. Kerby, and H. Calvert Temozolomide and treatment of malignant glioma Clin. Cancer Res. 6 2000 2585 2597
21. M. Zucchetti, C. Catapano, S. Filippeschi, E. Erba, and M. D'Incalci Temozolomide induced differentiation of K562 leukemia cells is not mediated by gene hypomethylation Biochem. Pharmacol. 38 13 1989 2069 2075
22. D. Baker, M. Wirth, and P. Statkevich Absorption, metabolism and excretion of 14C-temozolomide following oral administration to patients with advanced cancer Clin. Cancer Res. 5 2 1999 309 317
23. A. Chakravarti, M. Erkkinen, U. Nestler, R. Stupp, M. Mehta, K. Aldape, M. Gilbert, P. Black, and J. Loeffler Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms Clin. Cancer Res. 12 2006 4738 4746
24. Y.-H. Zhang, Z.-J. Yue, H. Zhang, G.-S. Tang, Y. Wang, and J.-M. Liu Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model Eur. J. Pharm. Biopharm. 76 3 2010 371 375
25. G. Huang, N. Zhang, X. Bi, and M. Dou Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity Int. J. Pharm. 355 1-2 2008 314 320
26. V. Shubayev, T.R. Pisanic 2nd, and S. Jin Magnetic nanoparticles for theragnostics Adv. Drug Deliv. Rev. 61 2009 467 477
27. F. Dilnawaz, A. Singh, S. Mewar, U. Sharma, N.R. Jagannathan, and S.K. Sahoo The transport of non-surfactant based paclitaxel loaded magnetic nanoparticles across the blood brain barrier in a rat model Biomaterials 33 10 2012 2936 2951
28. F. Dilnawaz, A. Singh, C. Mohanty, and S.K. Sahoo Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy Biomaterials 31 13 2010 3694 3706
29. A. Singh, F. Dilnawaz, S. Mewar, U. Sharma, N.R. Jagannathan, and S.K. Sahoo Composite polymeric magnetic nanoparticles for co-delivery of hydrophobic and hydrophilic anticancer drugs and MRI imaging for cancer therapy ACS Appl. Mater. Interfaces 3 2011 842 856
30. G. Mehta, A.Y. Hsiao, M. Ingram, G.D. Luker, and S. Takayama Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy J. Control. Release 164 2 2012 12 204
31. I. Dufau, C. Frongia, F. Sicard, L. Dedieu, P. Cordelier, F. Ausseil, B. Ducommun, and A. Valette Multicellular tumor spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics: application to the gemcitabine/CHK1 inhibitor combination in pancreatic cancer BMC Cancer 13 2012 12 15
32. F. Hirschhaeusera, H. Menneb, C. Dittfeldc, J. Westb, W. Mueller-Kliesera, and L.A. Kunz-Schughartc Multicellular tumorspheroids: an underestimated tool is catching up again J. Biotechnol. 148 1 2010 3 15
33. F. Pampaloni, E.G. Reynaud, and E.H. Stelzer The three dimension bridges the gap between cell culture and live tissue Nat. Rev. Mol. Cell Biol. 8 2007 839 845
34. F. Perche, N.R. Patel, and V.P. Torchilin Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model J. Control. Release 164 1 2012 95 102
35. S. Acharya, F. Dilnawaz, and S.K. Sahoo Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy Biomaterials 30 29 2009 5737 5750
36. K. Shield, C. Riley, M.A. Quinn, G.E. Rice, M.L. Ackland, and N. Ahmed α2β1 integrins affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis J. Carcinogen. 6 11 2007 1 15
37. P. Verma, V. Verma, P. Ray, and A.R. Ray Formation and characterization of three dimensional human hepatocyte cell line spheroids on chitosan matrix for in vitro tissue engineering applications In Vitro Cell. Dev. Biol. - Anim. 43 2007 328 337
38. A. Paramasivam, S. Sambanatham, J. Shabnam, S. Raghunandhakumar, B. Anandan, R. Rajiv, J. Vijayashree Priyadharsini, and G. Jayaraman Anti-cancer effects of thymoquinone in mouse neuroblastoma (Neuro-2a) cells through caspase-3 activation with down-regulation of XIAP Toxicol. Lett. 213 2012 151 159
39. R. Misra, S. Acharya, F. Dilnawaz, and S.K. Sahoo Sustained antibacterial activity of doxycycline-loaded poly(d,l-lactide-co-glycolide) and poly(epsilon-caprolactone) nanoparticles Nanomedicine (Lond.) 4 5 2009 519 530
40. S. Acharya, and S.K. Sahoo Sustained targeting of Bcr-Abl + leukemia cells by synergistic action of dual drug loaded nanoparticles and its implication for leukemia therapy Biomaterials 32 24 2011 5643 5662
41. T.H. Kim, C.W. Mount, W.R. Gombotz, and S.H. Pun The delivery of doxorubicin in 3-D multicellular spheroids and tumors in a murine xenograft model using tumor-penetrating triblock polymeric micelles Biomaterials 31 2010 7386 7397
42. P. Parhi, C. Mohanty, and S.K. Sahoo Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy Drug Discov. Today 8 2012 1044 1052
43. K.L. Nair, S. Jagadeeshan, S. Nair, and G.S. Vinod Kumar Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA Int. J. Nanomed. 6 2011 1685 1697
44. T.C. Chou Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res. 70 2010 440 446
45. G.Y. Lee, P. Kenny, E.H. Lee, and M.J. Bissell Three dimensional cultute model of normal and malignant breast epithelial cells Nat. Methods 4 2007 359 365
46. F. Wang, V.M. Weaver, O.W. Peterson, C.A. Larabell, S. Dedhar, P. Briand, R. Lupu, and M.J. Bissell Reciprocal interactions between beta-1 integroin and epidermal growth factor receptor in three-dimensional basement membrane breast culture; a different perspective in epithelial biology Proc. Natl. Acad. Sci. USA 95 1998 14821 14826
47. J.L. Horning, S.K. Sahoo, S. Vijayaraghavalu, S. Dimitrijevic, J.K. Vasir, T. Jain, and V. Labhasetwar 3-D tumor model for in vitro evaluation of anticancer drugs Mol. Pharm. 5 5 2008 849 862
48. M. Wartenberg, C. Fery, H. Diedershagen, J. Ritgen, H. Hescheler, and H. Saurer Development of an intrinsic p-glycoprotein-mediated doxorubicin resistance in quiescent cell layers of large, multicellular prostrate tumor spheroids Int. J. Cancer 1998 855 863
49. H. Maeda The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting Adv. Enzyme Regul. 41 2001 189 207
50. S.K. Sahoo, and V. Labhasetwar Nanotech approaches to drug delivery and imaging Drug Discov. Today 8 24 2003 1112 1120
51. R. Vacha, F.J. Martinex-Veracoechea, and D. Frenkel Receptor-mediated endocytosis of nanoparticles of various shapes Nano Lett. 11 2011 5391 5395